GHRS — GH Research PLC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1855129 ·
Last close
$20.45
Market Cap
$1.40B
52W High
$31.44
52W Low
$12.04
ADV30
266,762
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -19,448,000 | -15,146,000 | 372,349,000 | 345,053,000 | 12,859,000 |
| Mar 2026 | 0 | — | -18,748,000 | -18,967,000 | 275,267,000 | 242,652,000 | 11,890,000 |
| Dec 2025 | 0 | — | -16,699,000 | -14,137,000 | 288,230,000 | 246,251,000 | 8,527,000 |
| Sep 2025 | 0 | — | -16,535,000 | -14,020,000 | 302,022,000 | 249,654,000 | 10,625,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-51,703,000
Investing CF
$33,605,000
Financing CF
$111,736,000
CapEx
$-138,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.92
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-187,836,000
Inventory
—
Receivables
$1,295,000
ST Investments
$17,597,000
EBIT TTM
$-62,242,000
Pretax Income TTM
$-62,270,000
Interest Exp TTM
$28,000
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -60,676,000 | -48,258,000 | 288,230,000 | 8,527,000 | 279,703,000 | -43,552,000 |
| Dec 2024 | 0 | -50,246,000 | -38,961,000 | 188,273,000 | 9,322,000 | 178,951,000 | -42,285,000 |
| Dec 2023 | 0 | -41,221,000 | -35,587,000 | 226,300,000 | 7,332,000 | 218,968,000 | -33,336,000 |
| Dec 2022 | 0 | -30,675,000 | -22,456,000 | 254,362,000 | 4,546,000 | 249,816,000 | -26,199,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.85
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $20.00 · spot: $20.45 · call volume: 23 · put volume: 20Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NKTR | NEKTAR THERAPEUTICS | $1.39B | $40.80 | — |
| OMER | OMEROS CORP | $1.38B | $19.12 | — |
| RAPP | Rapport Therapeutics, Inc. | $1.43B | $29.85 | — |
| ANAB | ANAPTYSBIO, INC | $1.37B | $46.21 | — |
| AAPG | ASCENTAGE PHARMA GROUP INTERNATIONAL | $1.36B | $14.55 | — |
News headlines (Yahoo Finance, 1h cache)
Is GH Research (GHRS) Trading At A Premium To Fair Value?
2026-08-02 18:09 · Yahoo
GH Research gains on optimism surrounding potential Eli Lilly-Atai deal (GHRS)
2026-07-16 10:33 · Yahoo
GH Research Announces Publication of Phase 2a Postpartum Depression Results
2026-06-04 11:00 · Yahoo
Assessing GH Research (GHRS) Valuation After Key Phase 2b Results And Phase 3 Trial Plans
2026-05-16 20:12 · Yahoo
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-14 11:00 · Yahoo
GH Research Announces Pricing of $117.5 Million Underwritten Offering
2026-04-29 12:00 · Yahoo
Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight
2026-08-25 14:31 · Yahoo
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-06 11:00 · Yahoo
CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners
2026-07-27 14:38 · Yahoo
Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug
2026-07-16 17:53 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.